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The arthritis-associated HLA-B*27:05 allele forms
more cell surface B27 dimer and free heavy chain
ligands for KIR3DL2 than HLA-B*27:09
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Oliwia Rysnik2, Sravan Payeli4, Kirsty McHugh3, Grazia Dessole1,
Giovanni Porru1, Elisabetta Desogus5, Sarah Fiedler3, Soraya Ho¨lper3,
Amanda Carette3, Miguel Angel Blanco-Gelaz6, Alessandra Vacca1,
Matteo Piga1, Valentina Ibba1, Pietro Garau1, Giorgio La Nasa5,
Carlos Lo´pez-Larrea7,8, Alessandro Mathieu1, Christoph Renner4,
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Abstract
Objectives. HLA-B*27:05 is associated with AS whereas HLA-B*27:09 is not associated. We hypothesized
that different interactions with KIR immune receptors could contribute to the difference in disease asso-
ciation between HLA-B*27:05 and HLAB*27:09. Thus, the objective of this study was to compare the
formation of b2m-free heavy chain (FHC) including B27 dimers (B272) by HLA-B*27:05 and HLA-B*27:09
and their binding to KIR immunoreceptors.
Methods. We studied the formation of HLA-B*27:05 and HLA-B*27:09 heterotrimers and FHC forms
including dimers in vitro and in transfected cells. We investigated HLA-B*27:05 and HLA-B*27:09 binding
to KIR3DL1, KIR3DL2 and LILRB2 by FACS staining with class I tetramers and by quantifying interactions
with KIR3DL2CD3e-reporter cells and KIR3DL2-expressing NK cells. We also measured KIR expression on
peripheral blood NK and CD4 T cells from 18 HLA-B*27:05 AS patients, 8 HLA-B27 negative and 12 HLA-
B*27:05+ and HLA-B*27:09+ healthy controls by FACS staining.
Results. HLA-B*27:09 formed less B272 and FHC than HLA-B*27:05. HLA-B*27:05-expressing cells sti-
mulated KIR3DL2CD3e-reporter T cells more effectively. Cells expressing HLA-B*27:05 promoted
KIR3DL2+ NK cell survival more strongly than HLA-B*27:09. HLA-B*27:05 and HLA-B*27:09 dimer tetra-
mers stained KIR3DL1, KIR3DL2 and LILRB2 equivalently. Increased proportions of NK and CD4 T cells
expressed KIR3DL2 in HLA-B*27:05+ AS patients compared with HLA-B*27:05+, HLA-B*27:09+ and HLA-
B27 healthy controls.
Conclusion. Differences in the formation of FHC ligands for KIR3DL2 by HLA-B*27:05 and HLA-B*27:09
could contribute to the differential association of these alleles with AS.
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Introduction
HLA-B27 is strongly associated with a group of inflamma-
tory arthritic disorders collectively known as the SpA, typi-
fied by AS [1]. Theories for B27 disease involvement
include presentation of arthritogenic peptides to CD8 T
cells and induction of a proinflammatory misfolded protein
response (reviewed in [2]). B27 is expressed at the surface
of antigen presenting cells (APCs) as classical b2m-asso-
ciated class I heterodimers and disulphide-bonded b2m-
FHC forms including homodimers (termed B272) [35]. We
have proposed that disease results from B27 FHC
immune receptor interactions promoting arthritis [6, 7].
Such immune receptors include members of the killer
cell immunoglobulin-like receptor (KIR) and leukocyte im-
munoglobulin-like receptor (LILR) families.
HLA-B27 has multiple allelic variants [8], with some
alleles such as the prototypic dominant Caucasian HLA-
B*27:05 subtype being strongly associated with disease
while others such as HLA-B*27:09 are not associated [9].
Different B27 variants differ by one or more amino acid
substitutions, frequently resulting in altered residues
within their peptide binding clefts [10]. HLA-B*27:09 [11]
is not associated with disease and differs from HLA-
B*27:05 by one amino acid substitution. Aspartic acid at
position 116, in the a1 domain, is substituted to a histidine
(D116H).
KIR are expressed by NK cells and minor subsets of T
cells [12]. B27 binds to KIR family members with three
extracellular immunoglobulin-like domains (DoD1D2) and
a long cytoplasmic tail termed KIR3DL1/2. KIR3DL1
recognizes HLA-class I molecules including HLA-
B*27:05 that express the Bw4 epitope [13]. While both
HLA-B*27:05 FHC and heterodimer bind to KIR3DL1,
only FHC binds to KIR3DL2 [3, 14]. Although the sequence
of peptide bound to class I heterodimers affects KIR3DL1
and KIR3DL2 recognition, by contrast, recombinant B27
homodimer binding to KIR is independent of complexed
peptide [14]. KIR ligation inhibits activation-induced cell
death (AICD) [15, 16]. Ligation of KIR3DL2 by B27 FHC
promotes the survival of NK and Th17 cells [17, 18]. AS
patients have increased proportions of activated Th17 and
NK cells expressing KIR3DL2 [17, 18].
The LILR receptors LILRB1 and LILRB2 bind a broad
range of b2m-associated classical and non-classical class
I [19]. LILRB2 but not LILRB1 binds to b2m-free class I
heavy chain forms including HLA-B27 FHC and B27 dimer
[20, 21]. While LILRB1 is broadly expressed on B cell,
myeloid cells NK and T cells, LILRB2 is expressed by
cells of myeloid origin.
We hypothesized that the differential association of
HLA-B*27:09 with disease could be due to differences in
its interaction with KIR and LILR immune receptors com-
pared with HLA-B*27:05. Thus, we compared the forma-
tion of dimer and FHC by HLA-B*27:05 and HLA-B*27:09
and their interaction with KIR3DL1 and KIR3DL2. Our re-
sults suggest that differences in formation of FHC ligands
for KIR3DL2 by HLA-B*27:05 and HLA-B*27:09 could
play a role in the differential association of these alleles
with AS.
Materials and methods
HLA-B27 plasmid constructs
Prokaryotic plasmids and PHR-SIN lentiviral cassettes
for HLA-B*27:09 expression were generated by mutagen-
esis of pLM1-HLA-B*27:05 and PHR-SIN HLA-B*27:05,
respectively, using the QuickChange site-directed muta-
genesis kit (Invitrogen) following the manufacturer’s
instructions.
Lentiviral transduction of cell lines and
immunoprecipitations
LBL.721.221 cells (hereafter referred to as 221 cells) were
transduced with lentivirus expressing HLA-B*27:05 or
HLA-B*27:09 as described previously [21]. 20106 par-
ental 221 cells or 221B*27:05 and 221B*27:09 cells were
surface biotinylated with NHS-LC-biotin (Thermoscientific
UK Ltd) according to the manufacturers instructions.
Subsequently cells were stained with HC10 or W632 anti-
body (10mg), washed with ice-cold PBS and lysed as pre-
viously described [14]. Lysates were precipitated with
anti-mouse immunoglobulins Dynabeads, resolved by
non-reducing or reducing SDS-PAGE and western blots
developed with streptavidin-HRP (Sigma) or HRP-conju-
gated HC10.
KIR3DL2CD3e reporter cell assay
Jurkat T cell reporter cells transduced with a
KIR3DL2CD3e lentiviral expression cassette were pre-
pared as previously described [22]. All experiments for
cytokine assay were set up in RPM1640 medium
(Sigma) supplemented with 10% fetal calf serum and anti-
biotics [14]. 200 000 transduced T cells were incubated
with 200 000 parental 221 cells or HLA-B*27:05 or HLA-
B*27:09 transduced 221 cells for 24 h in with/without
HC10, W632, ME1 or isotype control IgG1/G2a mAbs
(MOPC 123 and MG1-45; Biolegend) at 50 mg/ml. Subse-
quently, supernatants were harvested for IL-2 ELISA ac-
cording to the manufacturer’s instructions (EBiosciences
Ltd UK).
Recombinant protein and tetramer generation
HLA-B27 heterodimer and homodimer were expressed
and produced as previously described [3]. Recombinant
biotinylated HLA-G dimers were prepared as previously
described [20]. Yields of refolded protein were calculated
by FPLC peak integration using the Unicorn software.
HC10 and HD6 ELISAs were performed as described pre-
viously [23].
Shared HLA-B*27:05 and HLA-B*27:09 peptides used
in this study: NRIKGIPKL; GRIGPNIRL; ARLQTALLV and
RRFFPYYVY [24]; and RRRWRRLTV [25]. HLA-B*27:05
peptides: RRIYDLIEL [26]; KRWIILGLNK (GAG, [27]).
SRYWAIRTR (Flu NP [28]) HLA-B*27:09 peptides:
TRIPKIQKL [24]. Proteins were biotinylated and tetramers
made with extravidin PE (Sigma) as previously described
[14].
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Tetramer staining
Tetrameric complexes were used to stain Baf3 cells trans-
fected with KIR3DL1, KIR3DL2, LILRB1 or LILRB2 recep-
tor as previously described [14].
Generation of NK cell lines
KIR3DL2+ NK cell lines were FACS-sorted from PBMC
using the DX31 mAb (Gift from Jo Phillips, DNAX), and
maintained by allogeneic stimulation as previously
described [17].
Coculture of NK cell lines with HLA-B27-expressing
APCs
NK cell lines were labelled with CFSE according to the
manufacturer’s instructions (Invitrogen). 100 000
500 0000 g-irradiated 221 APCs were incubated with
equal numbers of NK cells as previously described [17].
On day 5 cells were first stained for KIR3DL2 expression
and then stained with allophycocyanin-conjugated
Annexin V (BD Biosciences) and pacific blue Live-Dead
stain (Invitrogen) according to the manufacturer’s
instructions.
Patients and controls
18 HLA-B*27:05 AS patients (12 males and 6 females,
mean age 42.8 ± 8.2 years, mean disease duration
17.1 ± 11 years), 12 HLA-B*27:05 (mean age 35.8 years),
12 HLA-B*27:09 (mean age 37.5 years) and 8 HLA-B27
negative (mean age 36.6 years), sex-matched healthy
controls (HCs), were recruited under written informed con-
sent. All patients fulfilled the modified New York criteria for
Ankylosing Spondylitis and were not on anti-TNF-a drugs
at the time of taking samples. All patients and HCs se-
lected for this study were of Sardinian Caucasian origin
dating back at least three generations from both the ma-
ternal and paternal side. This study was approved by the
Institutional Ethical Committee of the University Hospital,
Cagliari, Italy (365/09/CE).
Reagents and antibodies
KIR3DL2 or KIR3DL1 expression was detected by indirect
staining with DX31 MAb or DX9 MAbs (Biolegend)
then Fluorescein isothiocyanate-conjugated goat F(ab’)2
anti-mouse (GAM) IgG (F0479, DAKO). Cells were then
stained with allophycocyanin-conjugated anti-CD56
(N901/NKH-1, Beckman Coulter, Fullerton, CA, USA),
PerCP-conjugated anti-CD3 (SK7, BD Biosciences), PE-
anti-CD4 (SFCI12T4D11, Coulter) or PE-Cy7-anti-CD4
(BD Biosciences).
The specificities of anti-HLA class I antibodies used in
this study are summarized in Table 1. HD6 antibody binds
to HLA-B27 dimers and multimers [23]. HC10 antibody
recognizes a linear epitope in HLA class I A, B and C
heavy chains incorporating amino acids 5564 of the
heavy chain [29]. W6/32 recognizes a discontinuous
epitope in the a2 and a3 domains of HLA-A, B and C
incorporating residue 121 of heavy chain formed by both
b2 m-associated and free forms of HLA class I [30, 31].
ME1 binds a conformational b2m-dependent epitope in
the a1 domain of HLA-B27, critically dependent on inter-
actions between residues 6771 [32].
Flow cytometric analysis
PBMCs were isolated by density gradient centrifugation
using Lympholyte-H (Cedarlane Laboratories, Hornby,
Ontario, Canada) and immediately stained for KIR expres-
sion. Stained cells were fixed with 1% paraformaldehyde
in PBS and analysed within 24 h. Flow cytometric analyses
were performed using a FACSCanto (BD Biosciences,
Franklin Lakes, NJ) and data were analysed with
FACSDiva 6.1.3 software (BD Biosciences).
Percentages of cells expressing KIR3DL2 and KIR3DL1
and KIR receptor density were evaluated on CD3/CD56+
NK and CD3+/CD4+ T cells. Briefly, for each sample, the
mean fluorescence channel was expressed as Relative
Channel Number on a linear scale, compared with five dif-
ferent standards of beads coated with defined mouse anti-
bodies and converted into Antibody Binding Capacity
(ABC) (DAKO Denmark). Saturating concentrations of pri-
mary and secondary antibodies were used. Fluorescence
correlates with the number of bound primary antibody mol-
ecules on the cells and on the beads and ABC units cor-
respond to the number of binding sites [33].
Data analysis
Values are expressed as mean percentages ± S.D. positive
cells and as mean cell surface antigen density in ABC
units. Differences between AS and HCs were analysed
by one-way analyses of variance (ANOVA) with a Bonfer-
roni post-test and a two-tailed unpaired t-test with
Welch’s correction. Statistical analysis was performed
using Prism 5.0 software (GraphPad Inc.).
Results
HLA-B*27:05 forms more cell surface FHC forms than
HLA-B*27:09
The specificities of anti-HLA-B27 and anti-HLA-class I
antibodies used in this study are summarized in Table 1.
The ME1 antibody recognizes b2m-associated HLA-B27,
whereas W6/32 has been reported to recognize both
b2m-associated and b2m-free forms of HLA-B27 and
other HLA class I [30, 32, 34]. HC10 antibody binds to
HLA-B27 and other b2m-free HLA class I heavy chains
and HD6 antibody recognizes dimeric and multimeric
forms of HLA-B27 b2m-FHC [23, 29]. We first compared
levels of expression of B27 b2m-FHC on 221 cells which
expressed comparable levels of HLA-B*27:05 or HLA-
B*27:09 of ME1- and W6/32-reactive B27 by FACS ana-
lysis (Fig. 1A and B). Both HC10 and HD6 antibodies
stained 221B*27:05 more strongly than 221B*27:09 cells
(Fig. 1A and B).
Next we immunoprecipitated HC10-reactive class I
heavy chains from surface biotinylated 221B*27:05 and
221B*27:09 cells. Immunoprecipitates were resolved
by SDS-PAGE and analysed by western blot with
HRP-conjugated streptavidin or HRP-conjugated HC10
(Fig. 1C). Increased quantities of dimers and multimeric
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FHC forms were detectable in immunoprecipitates from
221B*27:05 cells compared with 221B*27:09 cells
(Fig. 1C). In the presence of dithiothreitol, higher molecular
weight forms reduced to monomeric heavy chains
(Fig. 1C). W6/32 immunoprecipitated monomeric B27
heavy chains from 221B*27:05 and 221B*27:09 cells
(Fig. 1C). Western blots of whole cell lysates from
221B*27:05 and 221B*27:09 cells show equivalent levels
of expression of HC10-reactive class I heavy chains
(Fig 1C).
221B*27:05 cell lines interact more strongly with
KIR3DL2 than 221B*27:09
We asked whether increased levels of expression of FHC
on 221B*27:05-expressing cells compared with HLA-
B*27:09-expressing cell lines would result in enhanced
interactions with KIR3DL2. KIR3DL2CD3"-expressing
Jurkat T reporter cells produce more IL-2 when stimulated
with B27-expressing B cell lines compared with cells ex-
pressing other HLA class I [22]. KIR3DL2CD3"-expressing
Jurkat reporter cells consistently produced more IL-2
when stimulated with HLA-B*27:05-expressing 221 cells
compared with stimulation with HLA-B*27:09-expressing
cells (Fig. 2A). KIR3DL2CD3"-reporter cell B27 inter-
actions were inhibited by FHC and dimer reactive antibo-
dies HC10 and HD6, respectively, and by W6/32 but not
by isotype control mAbs (Fig. 2A). W6/32 has been re-
ported to bind to some forms of b2m-free HLA class I
including HLA-B27. ME1 antibody which binds to b2m-
associated HLA-B27 had no effect (Fig. 2A).
We studied survival of KIR3DL2-expressing cells stimu-
lated with transduced 221 cells for 5 days. Viable NK cells
do not stain with Annexin V and dead stains. 221B*27:05
cells stimulated greater survival of KIR3DL2-expressing
NK cells compared with 221B*27:09 cells (Fig. 2B and
C). NK cell survival was reduced by stimulation in the
presence of HC10, W632 and anti-KIR3DL2 (DX31)
mAbs (Fig. 2B and C).
HLA-B*27:05 forms more heavy chain homodimer
(B272) in vitro than HLA-B*27:09
In order to determine whether increased dimer formation
is an inherent property of HLA-B*27:05, we next asked
whether HLA-B*27:05 and HLA-B*27:09 subtypes differed
in their ability to form heavy chain homodimers in vitro.
Identical quantities of HLA-B*27:05 and HLA-B*27:09
heavy chains were refolded with b2m and B27-binding
peptide or without b2m and the yield and purity of result-
ing B27 heterodimers and dimers assessed biochemically
by FPLC and SDS PAGE.
Fig. 3A shows representative FPLC plots of refolded
protein from HLA-B*27:05 and HLA-B*27:09, folded in
parallel in the presence of b2m and peptide. A panel of
HLA-B*27:05- and HLA-B*27:09-specific peptides and
shared epitopes (summarized in Materials and methods
section) were used. Peaks corresponding to homodimers
and heterodimers, defined by SDS PAGE, were quantified
by gel exclusion chromatography. Refolds were per-
formed for seven peptides and repeated up to five
times. A representative purification is shown in Fig. 4A
and the yields of dimeric and heterodimeric protein, ex-
pressed as a proportion of total dimeric and heterodimeric
protein, are summarized in Fig. 3B. Although we consist-
ently observed heterodimers, in some refolds with HLA-
B*27:09 dimer peaks were absent (results not shown).
HLA-B*27:05 consistently yielded more B27 dimer com-
pared with HLA-B*27:09.
HLA-B*27:05 heavy chains folded in the absence of
b2m consistently yielded more B27 dimer compared
with HLA-B*27:09 (Fig. 3C). Recombinant HLA-B*27:05
and HLA-B*27:09 dimers bound equivalently strongly to
HC10 antibody in ELISA (Fig. 3D). In contrast HLA-
B*27:05 dimers bound more strongly to HD6 antibody
compared with HLA-B*27:09 dimers in ELISA (Fig. 3D).
As previously observed neither HLA-G dimers nor HLA-
B27 heterodimers bound to HD6 antibody (Fig. 3D and
results not shown).
Recombinant HLA-B*27:05 and HLA-B*27:09 dimer
tetramers bind similarly to KIR3DL1, KIR3DL2 and
LILRB2; HLA-B*27:05 and HLA-B*27:09 heterodimers
bind differently to KIR3DL1
Differences in KIR3DL2 binding to HLA-B*27:05 and HLA-
B*27:09 could occur as a consequence of differences in
their propensity to form B27 dimers and other FHC
species and/or differences in their interaction with KIR re-
ceptors. In order to address whether HLA-B*27:05 and
HLA-B*27:09 bound differently to immune receptors, we
studied the ability of HLA-B*27:05 and HLA-B*27:09 dimer
and heterodimer tetramers to stain KIR3DL1/2-
TABLE 1 Summary of the anti-HLA class I antibodies used in this study
Antibody Isotype Specificity References
HD6 IgG1 b2m-free HLA-B27 dimers and multimers [23]
HC10 IgG2a b2m-free HLA-A, B and C heavy chain. Linear epitope incorporates residues 55-64 of
the HLA class I heavy chain
[29]
ME1 IgG1 b2m-associated HLA-B27 and some other HLA-B alleles. Recognizes a conformational
epitope in the a1 helix criticall dependent on interaction between residues 67 and 71
[32]
W6/32 IgG2a Recognizes a discontinuous epitope in the a2 and a3 domains of HLA-A, B and C
incorporating residue 121 of heavy chain formed by both b2m-associated and free
forms of HLA-class I
[30, 31, 34]
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transduced cells. In parallel we stained LILRB1- and
LILRB2-transduced cells with tetramers to control for
tetramer integrity.
HLA-B*27:05 and HLA-B*27:09 dimer tetramers stained
LILRB2-transduced Baf3 cells similarly (Fig. 4A). Neither
HLA-B*27:05 nor HLA-B*27:09 dimer tetramers bound
LILRB1-transduced Baf3 cells (results not shown).
HLA-B*27:05 and HLA-B*27:09 dimers bound KIR3DL1
and KIR3DL2 transfectants similarly (Fig. 4B).
HLA-B*27:05 heterodimer tetramers formed with FluNP
and Gag epitopes stain KIR3DL1 transfectants. In contrast
HLA-B*27:09 heterodimer tetramers complexed with
these epitopes did not stain KIR3DL1-transfected cells
as strongly as HLA-B*27:05 heterodimers, although
FIG. 1 HLA-B*27:05 forms more cell surface free heavy chain dimer and multimer than HLA-B*27:09.
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Representative FACS stains of HLA-B*27:05 and HLA-B*27:09 transduced 221 cells with in (A) W632 and HC10, (B) ME1
and HD6 antibodies. Representative stain from one of four independent stains. MFIs for HLA-B*27:05 transduced 221
cells stained with ME1, W632, HC10 and HD6 were and respectively. MFIs for HLA-B*27:09 transduced 221 cells stained
with ME1, W632, HC10 and HD6 were and respectively. (C) Western blot with streptavidin HRP and HC10-HRP of HC10
and W632 immunoprecipitates from cell-surface biotinylated 221B*27:05 and 221B*27:09 cells. Lower panels (+DTT):
western blots of reduced samples of HC10 and W632 immunoprecipitates and whole cell lysates from cell-surface
biotinylated 221B*27:05 and HLA-B*27:09 cells. Far right hand panels: western blots with HC10-HRP of whole cell lysates
from 221B*27:05 and HLA-B*27:09 cells before immunoprecipitation. Representative western blots from one of three
independent experiments.
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these tetramers nevertheless stained LILRB1/ILT2-trans-
fected cells equivalently (Fig. 4C and D).
Increased proportions of peripheral blood NK and
CD4 T cells express KIR3DL2 in HLA-B*27:05+ AS
patients compared with healthy B*27:05+, B*27:09+
and B27 negative controls
We have previously demonstrated increased proportions
of peripheral blood NK and CD4 T cells expressing
KIR3DL2 in HLA-B*27:05+ SpA patients compared with
B27 RA, ulcerative colitis and HCs [17, 18]. Although
KIR3DL2 is also expressed on CD8 T cells, we did not
observe significant increases in the proportions of CD8
T cells expressing KIR3DL2 in SpA patients in these stu-
dies. Thus, we chose to focus on studying on KIR3DL2
expression by NK and CD4 T cells in this study. Our re-
sults indicated a reduced propensity of HLA-B*27:09 to
form dimeric and other B27 FHC forms and decreased
FIG. 2 KIR3DL2 binds more strongly to cell surface HLA-B*27:05 than HLA-B*27:09.
%
V
ia
bl
e
 C
e
lls
-
+
22
1
+
22
1B
*
27
05
+
22
1B
*
27
09
+
22
1B
*
27
05
+
igG
2a
+
22
1B
*
27
05
+
HC
10
+
22
1B
*
27
05
+
DX
31
0
10
20
30
40
50
IL
2 
pg
/m
l
-
+ 2
21 +
+ Ig
G 2
a
+ Ig
G 1
+M
E1
+H
C 1
0
+H
D 6
+W
63
2 +
+ Ig
G 2
a
+ Ig
G 1
+M
E1
+H
C1
0
+W
63
2
+H
D 6
0
50
100
150
+221B*2705 +221B*2709
A
CB
+221B*2705
D
ead Stain PB
Annexin V APC
P<0.001
* **
** **
(A) IL-2 secretion by KIR3DL2CD3e-reporter Jurkat T cells stimulated with (A) HLA-B*27:05 and HLA-B*27:09 transduced
221 cells. Effect of HC10, HD6, ME1 and W632 MAbs on IL-2 secretion by KIR3DL2CD3e-transduced Jurkat T cells is
also shown. Representative of three independent experiments. (B) Left hand panels: proportions of viable (Annexin V,
Live-Dead negative) KIR3DL2 + NK cells after 6 day stimulation with parental 221 cells or 221B*27:05 and 221B*27:09
cells. Right hand panels: pproportions of viable (Annexin V, Live-Dead negative) KIR3DL2 + NK cells after 6 day stimu-
lation with 221B*27:05 cells and anti-KIR3DL2 (DX31) or HC10 and W632 antibodies or isotype control antibody (IgG2a).
Representative FACS stains from one of three independent experiments with an NK cell line from a healthy B27 control.
(C) Proportions of viable KIR3DL2 + NK cells after 6 day stimulation with 221, 221B*27:05 or 221B*27:09 cells or
221B*27:05 cells with anti-KIR3DL2 (DX31), HC10, W632 or isotype control (IgG2a) antibodies. Mean proportions of
surviving cells ± 1S.D. from three independent experiments. *P< 0.05 and **P< 0.01 ANOVA.
www.rheumatology.oxfordjournals.org 1957
HLA-B*27:05 forms more KIR3DL2 ligand than HLA-B*27:09 in AS
interactions with KIR3DL2 occurring as a consequence.
We predicted that this would translate into differences in
the proportions of NK and CD4 T cells expressing
KIR3DL2 in HLA-B*27:09+ individuals compared with
HLA-B*27:05+ AS patients. Thus we compared the pro-
portions of NK and CD4 T cells expressing KIR3DL2 in the
peripheral blood of HLA-B*27:05+ AS patients and HLA-
B*27:05, HLA-B*27:09 and HLA-B27 HCs by ex vivo
FACS staining. We also studied the proportions of NK
and CD4 T cells in each of these groups expressing
KIR3DL1 and KIR3DS1 which bind to HLA-B27 and
have been reported to be associated with SpA respect-
ively. We observed increased proportions of NK and CD4
T cells expressing KIR3DL2 in the peripheral blood of AS
patients with HLA-B*27:05 compared with healthy HLA-
B*27:05+, HLA-B*27:09+ and HLA-B27 negative controls
(Fig. 5A and B). In contrast we did not see any significant
differences in the proportions of NK and CD4 T cells ex-
pressing KIR3DL1 and KIR3DS1 between each of these
groups. A mean of 20.7 ± 11.9 AS NK cells expressed
KIR3DL1 compared with 13.0 ± 8.9 (P= ns) HLA-B*27:05
HCs, 12.8 ± 10.7 HLA-B*27:09 HCs (P= ns) and
23.7 ± 17.7 HLA-B27 negative (P= ns) (results expressed
as mean values ± 1S.D.). AS patient NK cells expressed a
mean of 9301.2 ± 3175.5 ABC units KIR3DL1 compared
with 7429.5 ± 4784.2 units in HLA-B*27:05 HCs (P= ns),
6027.4 ± 4082.6 units in HLA-B*27:09 HCs (P= ns) and
7512 ± 5088 units in HLA-B27 negative HCs (P= ns).
0.5% ± 0.4% AS CD4 T cells expressed KIR3DL1 com-
pared with an aggregated mean of 0.3 ± 0.3 in the HC
groups (P= ns). KIR3DS1 staining was only detected in
one HLA-B*27:09 HC in this study.
Discussion
Here we show that HLA-B*27:05, which is strongly asso-
ciated with SpA, forms more B27 FHC ligands for
KIR3DL2 compared with HLA-B*27:09 which is not asso-
ciated with disease.
We detected more cell surface heavy chain dimers and
FHC forms on 221B*27:05 compared with 221*27:09 cells
biochemically. 221B*27:05 cells also stained more
strongly than 221B*27:09 cells with HD6 antibody, which
recognizes B27 FHC dimers and other FHCs [23]. Western
blots showed that 221B*27:05 and 221B*27:09 cells ex-
pressed equivalent amounts of class I heavy chains in cell
lysates. Moreover 221B*27:05 and 221B*27:09 cells ex-
pressed similar levels of cell surface ME1 and W6/32-re-
active B27. These findings support previous preliminary
work showing increased proportions of heavy chain
dimers on the surface of 221B*27:05 cells compared
with 221B*27:09 cells [35].
We have previously shown that B27 FHC is a
ligand for KIR3DL2 [3, 22]. Consistent with 221B*27:05
cells expressing more cell surface FHC forms than
221B*27:09, 221B*27:05-expressing cells stimulated
KIR3DL2CD3e reporter cells to a greater extent than
221B*27:09. Moreover KIR3DL2 ligation by HLA-B*27:05
promoted leucocyte survival to a greater degree than
HLA-B*27:09.
Reduced interactions with KIR3DL2 could result from
decreased cell surface ligand density and/or differences
in the strength of ligand binding to these receptors.
HLA-B*27:05 and HLA-B*27:09 dimer tetramers bound
FIG. 3 HLA-B*27:05 forms more heavy chain homodimer
(B272) in vitro than HLA-B*27:09.
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(D) ELISA of HLA-B*27:05 (B*27:052), HLA-B*27:09
(B*27:092) and HLA-G dimers (HLA-G2) with HC10, W632
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FIG. 4 Similar binding of HLA-B*27:05 and HLA-B*27:09 dimers to KIR3DL1, KIR3DL2 and LILRB2. HLA-B*27:05 and
HLA-B*27:09 heterodimers bind differently to KIR3DL1.
A
B
Tetramer PE
0
20
40
60
80
100
%
 o
f M
ax
KIR3DL1
Tetramer PE
0
20
40
60
80
100
%
 o
f M
ax
KIR3DL2
C Flu NP
Tetramer PE
0
20
40
60
80
100
Tetramer PE
0
20
40
60
80
100
%
 o
f M
ax
%
 o
f M
ax
%
 o
f M
ax
%
 o
f M
ax
HIV Gag
KIR3DL1
KIR3DL1
Tetramer PE
0
20
40
60
80
100
LILRB1
LILRB1
Tetramer PE
0
20
40
60
80
100
Tetramer PE
0
20
40
60
80
100
%
 o
f M
ax
D
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
100 101 102 103 104
100 101 102 103 104 100 101 102 103 104
Tetramer PE
0
20
40
60
80
100
%
 o
f M
ax
B*27:052
B*27092
Extravidin PE
LILRB2
B*27:052
B*27:092
Extr PE B*27:052
B*27:092
Ext PE
B*27:05
B*27:09
Extravidin PE B*27:05
B*27:09
Extravidin PE
B*27:05
B*27:09
Extravidin PE B*27:05
B*27:09
Extravidin PE
Ext PE B*27:052
B*27:05
B*27:09
(A) Representative FACS staining of LILRB2-transduced Baf3 cells with HLAB*27:05 (B*27:052) and HLA-B*27:09
(B*27:092) dimer tetramers. Cells were stained with extravidin PE (EX PE) as a negative control stain. (B) Representative
FACS staining of KIR3DL1- and KIR3DL2-transduced Baf3 cells with HLA-B*27:05 (B*27:052) and HLA-B*27:09
(B*27:092) heavy chain dimer tetramers. Representative staining of KIR3DL2-transduced Baf3 cells with HLA-B*27:05
(B*27:05) and HLA-B*27:09 heterodimer (B*27:09) tetramers. Staining with HLA-B*27:05 (B*27:052) heavy chain dimer
tetramers (B272) is shown for comparison. Cells were stained with extravidin PE (EX PE) as a negative control stain.
(C) Representative FACS staining of KIR3DL1- and LILRB1-transduced Baf3 cells with HLA-B*27:05 (B*27:05) and HLA-
B*27:09 (B*27:09) heterodimer tetramers formed with the FluNP epitope. Cells were stained with extravidin PE (EX PE) as
a negative control stain. (D) Representative FACS staining of KIR3DL1- and LILRB1-transduced Baf3 cells with HLA-
B*27:05 (B*27:05) and HLA-B*27:09 (B*27:09) heterodimer tetramers formed with the HIV GAG epitope. Cells were
stained with extravidin PE (EX PE) as a negative control stain.
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equivalently to KIR3DL2. Thus, the reduced interaction of
HLA-B*27:09 with KIR3DL2 compared with HLA-B*27:05
probably occurs as a consequence of lower levels of B27
FHC forms expressed by this allele.
HLA-B*27:09 heterodimer tetramers bound more
weakly or did not bind to KIR3DL1 compared with HLA-
B*27:05 heterodimers with the same peptide. The amino
acid change of aspartic acid in HLA-B*27:05 to histidine in
HLA-B*27:09 at position 116 influences the conformation
of bound peptide and recognition by CD8 T cells [36].
KIR3DL1 recognition of HLA-Bw4 is dependent on the
sequence of the C-terminal positions 7 and 8 of bound
peptide [13]. Differences in the preferred C-terminal
anchor and the C-terminal conformations of bound pep-
tide between HLA-B*27:05 and HLA-B*27:09 could thus
affect KIR3DL1 recognition.
HLA-B*27:05+ SpA patients had increased proportions
of KIR3DL2-expressing peripheral blood NK and CD4
T cells compared with healthy HLA-B*27:05+, HLA-
B*27:09+ and B27 controls. Although we have previously
shown increased KIR3DL2 expression on leucocytes from
B27+SpA patients compared with leucocytes from arthritis
and B27 negative HCs, we did not study expression on
HLA-B*27:09 controls [17, 18]. KIR3DL2 + CD4 Th17 cells,
highly enriched for the expression of Th17 phenotypic mar-
kers, are expanded in SpA patients [18]. Increased levels of
HLA-B27 FHC dimers and FHC are expressed by mono-
cytes from SpA patients [23, 3739]. Thus increased ex-
pression of B27 FHC ligands for immune receptors such
as KIR3DL2 in SpA patients with HLA-B*27:05 could pro-
mote the survival of proinflammatory leucocytes.
Our results suggest that the increased binding of HLA-
B*27:05 FHC to KIR3DL2 is primarily due to increased
formation of FHC compared with HLA-B*27:09. HLA-
B*27:05 and HLA-B*27:09 dimer tetramers bound similarly
to KIR and LILRB2 receptors. HLA-B*27:05 shows an
increased propensity to form dimers compared with
HLA-B*27:09. The reactive cysteine 67 is critical for B27
heavy chain dimer formation [5]. Differences in residues at
position 116 of the class I heavy chain affect both the
reactivity of cysteine 67 and the way in which these two
alleles fold and unfold and could affect dimer and FHC
formation [5, 40, 41].
B27 FHC forms including B27 dimers form more readily
from b2m-associated HLA-B27 heterodimers subopti-
mally loaded with peptide [5]. It is possible that HLA-
B*27:05 is less stringent in the optimization of peptide
cargo compared with HLA-B*27:09. Thus, the increased
instability of b2m-associated HLA-B*27:05 compared with
HLA-B*27:09 could lead to the formation of more B27
FHC forms in disease.
Here we show that disease-associated HLA-B*27:05
forms more B27 heavy chain dimer and FHC in vitro and
on transfected cells than HLA-B*27:09, which is not asso-
ciated with disease. Increased expression of cell surface
B27 FHC forms by HLA-B*27:05 correlates with stronger
interaction with KIR3DL2 compared with HLAB*27:09.
HLA-B*27:05 + AS leucocytes have increased proportions
of KIR3DL2. Thus, the increased propensity of HLA-
B*27:05 to form FHC ligand compared with HLA-B*27:09
results in enhanced survival of KIR3DL2-expressing
leucocytes and could contribute to the differential associ-
ation of these B27 alleles with AS.
FIG. 5 Increased expression of KIR3DL2 by leucocytes
from HLA-B*27:05+ patients compared with HLA-B27
and HLA-B*27:05+ and HLA-B*27:09+ healthy controls
(HCs).
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(A) Left hand panel: percentage of NK cells expressing
KIR3DL2 in HLA-B*27:05 + SpA patients, HLA-B*27:05+
HC, HLA-B*27:09 HC and HLA-B27 negative HC.
Percentages of NK cells expressing KIR3DL2 were
35.6 ± 13.6 (mean ± 1S.D.), 20.3 ± 6.3 (P= 0.0004),
17.9 ± 11.3 (P= 0.0007) and 22.3 ± 8.5 (P= 0.007) for each
of the respective groups. Right hand panel: level of ex-
pression of KIR3DL2 (ABC units) by SpA patient NK cells,
HLA-B*27:05+, HLA-B*27:09+ and HLA-B27 HC. HLA-
B*27:05+ SpA patients expressed 1571 ± 631.9 ABC units
compared with 1038 ± 235.7 units (P= 0.003) for HLA-
B*27:05 HC, 1049 ± 331.5 (P= 0.007) for HLA-B*27:09+ HC
and 961 ± 318 units (P= 0.003) for HLA-B27 negative HC.
(B) Left hand panel: percentages of CD4 T cells expressing
KIR3DL2 in HLA-B*27:05 + SpA patients, HLA-B*27:05+,
HLA-B*27:09 + and HLA-B27 negative HC. A mean of
1.8 ± 1.3 SpA CD4 T cells, 0.8 ± 0.4 HLA-B*27:05 HC
(P= 0.01), 0.9 ± 0.3 B*27:09 HC (P= 0.009) and 1.0 ± 0.7
(P= 0.04) B27 negative HC expressed KIR3DL2. Right hand
panel: SpA patient CD4 T cells expressed 1232 ± 513.8
ABC units of KIR3DL2, compared with 878.3 ± 199 HLA-
B*27:05 HC (P= 0.011), 859.3 ± 288.7 HLA-B*27:09 HC
(P= 0.016) and 847 ± 321 B27 negative HC (P= 0.030).
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Rheumatology key messages
. The SpA-associated HLA-B*27:05 subtype forms
more B27 free heavy chain ligands for KIR3DL2
than HLA-B*27:09.
. The AS-associated HLA-B*27:05 subtype promotes
greater survival of KIR3DL2-expressing leucocytes
than HLA-B*27:09.
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